Back to Search
Start Over
Can Targeted Protein Degradation Technology Provide a Potential Breakthrough in the Development of Anti-AD Drugs?
- Source :
-
ACS chemical neuroscience [ACS Chem Neurosci] 2024 Oct 02; Vol. 15 (19), pp. 3434-3436. Date of Electronic Publication: 2024 Sep 18. - Publication Year :
- 2024
-
Abstract
- Recent advancements in Alzheimer's disease (AD) research have led to the approval of lecanemab and donanemab, highlighting the effectiveness of amyloid-beta (Aβ) degradation as a treatment for AD. The prospect of small molecule Aβ degraders as a potential treatment, which utilizes emerging targeted protein degradation technology, is exciting, given their ability to address some of the limitations of current therapies and their promising future in AD treatment. Despite facing challenges, these degraders are poised to become a future treatment option, harnessing scientific breakthroughs for more targeted and effective AD therapy.
Details
- Language :
- English
- ISSN :
- 1948-7193
- Volume :
- 15
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- ACS chemical neuroscience
- Publication Type :
- Academic Journal
- Accession number :
- 39354828
- Full Text :
- https://doi.org/10.1021/acschemneuro.4c00590